OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Jones on the Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in CRC

July 12th 2021

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.

Dr. Pothuri on Treatment Considerations for PARP Inhibitors in Ovarian Cancer

July 12th 2021

Bhavana Pothuri, MD, discusses treatment considerations for PARP inhibitors in patients with ovarian cancer.

Dr. Sereti on the Preclinical Efficacy of NOV202 Plus Olaparib in BRCA1/2-Mutated Prostate Cancer

July 10th 2021

Evangelia Sereti, MSc, PhD, discusses the preclinical efficacy of NOV202 plus olaparib in BRCA1/2-mutated prostate cancer cells.

Dr. Wagaskar on the Rationale to Evaluate the Obesity Paradox in Prostate Cancer

July 10th 2021

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Dr. Sperling on Managing CAR T-Cell Therapy–Related Toxicities in Multiple Myeloma

July 9th 2021

Adam Sperling, MD, PhD, discusses managing CAR T-cell therapy–related toxicities in multiple myeloma.

Dr. Tagawa on Tumor Targeting With Radionuclides in Prostate Cancer

July 8th 2021

Scott T. Tagawa, MD, MS, FACP, discusses tumor targeting with radionuclides in prostate cancer.

Dr. Carey on the Clinical Implications of the FeDeriCa trial in HER2+ Breast Cancer

July 8th 2021

Lisa A. Carey, MD, FASCO, discusses the clinical implications of the phase 3 FeDeriCa trial in HER2-positive breast cancer.

Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 Vaccines

July 8th 2021

Renold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.

Dr. O’Malley on the Efficacy of Pembrolizumab in Advanced Ovarian Cancer

July 8th 2021

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

Dr. Sperling on Future Research Directions With Ide-Cel in Multiple Myeloma

July 8th 2021

Adam Sperling, MD, PhD, discusses future research directions with idecabtagene vicleucel for the treatment of patients with multiple myeloma.

Dr. Shah on Efforts to Combat Resistance to BTK Inhibitors in MCL

July 7th 2021

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

Dr. Wong on Treatment Goals in Systemic Amyloidosis

July 7th 2021

Sandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.

Dr. Phillips on the Next Steps With Venetoclax/Lenalidomide/Rituximab in MCL

July 7th 2021

Tycel Jovelle Phillips, MD, discusses the next steps in evaluating the combination of venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

Dr. Kahl on Differences in Mechanisms of Action of PI3K Inhibitors in Follicular Lymphoma

July 7th 2021

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.

Dr. Leonard on the Future of PI3K Inhibitors in Follicular Lymphoma

July 7th 2021

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

Dr. Pemmaraju on Characteristics of Disease Progression in Myelofibrosis

July 7th 2021

Naveen Pemmaraju, MD, discusses the characteristics of disease progression in patients with myelofibrosis.

Dr. Mauro on Managing Symptom Burden in Myelofibrosis

July 6th 2021

Michael J. Mauro, MD, discusses managing symptom burden in patients with myelofibrosis.

Dr. Abedin on the Safety and Efficacy of Ibrutinib in CLL

July 6th 2021

Sameem Abedin, MD, discusses the safety and efficacy of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Dr. Leonard on the Potential for Combinations With PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.

Dr. Kahl on Selecting Between PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.